Research programme: MEP pathway inhibitors - Ferrer

Drug Profile

Research programme: MEP pathway inhibitors - Ferrer

Alternative Names: GF-011802-00; GF-011806-00

Latest Information Update: 09 Jan 2009

Price : $50

At a glance

  • Originator Ferrer
  • Class
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 09 Jan 2009 Preclinical development is ongoing in Spain
  • 24 Jan 2006 Preclinical trials in Bacterial infections in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top